Form 8-K - Current report:
SEC Accession No. 0001193125-25-122872
Filing Date
2025-05-20
Accepted
2025-05-20 08:59:10
Documents
14
Period of Report
2025-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d945177d8k.htm   iXBRL 8-K 31738
2 EX-10.1 d945177dex101.htm EX-10.1 50612
3 EX-10.2 d945177dex102.htm EX-10.2 92273
  Complete submission text file 0001193125-25-122872.txt   333497

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rani-20250520.xsd EX-101.SCH 2877
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rani-20250520_lab.xml EX-101.LAB 17978
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rani-20250520_pre.xml EX-101.PRE 11276
16 EXTRACTED XBRL INSTANCE DOCUMENT d945177d8k_htm.xml XML 3655
Mailing Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131
Business Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700
Rani Therapeutics Holdings, Inc. (Filer) CIK: 0001856725 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40672 | Film No.: 25966414
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)